Roivant Sciences Ltd. (ROIV) Tops Q3 EPS by 634c

Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q3 EPS of $6.03, $6.34 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $37.14 million versus the consensus estimate of $32.41 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c